Financial Results for the First Quarter of Fiscal Year Ending March 31, 2011
August 5, 2010
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL http://www.terumo.com/): 4543: Yutaro Shintaku, Representative Director and President: Tetsuya Kumei, General Manager, Corporate Communication Dept.
: +81 / 3-3217 -6550

Company code number
Representative:
Please address all communications toPhone

1. Consolidated financial highlights for the interim period ended June 2010
(From April 1, 2010 to June 30, 2010)(1) Consolidated financial results
Net sales

Operating income(Millions of yen)%

81,234
77,467

Three months ended June, 2010
Three months ended June, 2009

Ordinary income(Millions of yen)%

15,946
16,476

4.9(0.4)(Millions of yen)

12,554
16,934(3.2)
1.4

Net income%(Millions of yen)

8,792
10,812(25.9)(10.2)%(18.7)(22.9)Net income per share, fully
diluted

Net income per share
(Yen)

(Yen)

－
46.30
Three months ended June, 2010
56.94－
Three months ended June, 2009
(Note) Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.
The amount shown above ignore values of less than a million yen.
(2) Consolidated financial position
Total assets

Capital asset ratio

Net assets

Net assets per share(Millions of yen)

(Millions of yen)

%

(Yen)

395,894
425,507311,807317,13978.7
74.5

1,640.88
1,668.93

Jun 30, 2010
Mar 31, 2010

(Note) Shareholders' equity : June 30, 2010: 311,593 million yen, March 31, 2010: 316,921 million yen.
The amount shown above ignore values of less than a million yen.

2. Dividends

1st quarter

Fiscal year ended March 31, 2010
Fiscal year ending March 31, 2011
Fiscal year ending March 31, 2011 (forecast)

Dividends per share
2nd quarter 3rd quarter 4th quarter

total(Yen)

(Yen)

(Yen)

(Yen)

(Yen)

－－

16.00

－

16.00

32.00

16.00

－

16.00

32.00

(Note) Revise of dividends forecast : None

3. Consolidated forecast for the year ending March 2011 (From April 1, 2010 to March 31, 2011)
Operating income

Net salesInterim year ending September, 2010
Fiscal year ending March, 2011

Net income
per share

Net income

Ordinary income(Millions of yen)%

(Millions of yen)%(Millions of yen)%

(Millions of yen)%

164,000
333,000

3.8
5.4

32,60065,2000.2
3.0

32,50065,0000.8
2.2

20,80041,500

0.1
1.9(Yen)109.53218.54

1. Forecast for fiscal year ending March, 2011 which was announced on May 12, 2010 has not been revised.
(Assumed exchange rate for fiscal year ending March, 2011: USD1=JPY90, EUR1=JPY120)
2. Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these areforecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results
may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic
conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

14. Consolidated Financial Statements(1) Consolidated Balance Sheets(Millions of yen)
As of June 30, 2010
Amount(Assets)
I Current assets

209,271%
52.9%

As of March 31, 2010
Amount230,431

Cash and deposits

73,72590,102

Notes and accounts receivable-trade70,27871,798Merchandise and finished goods

31,87734,180Work in process

6,109

6,143

Raw material and supplies

14,84914,741

Deferred tax assets

7,510

9,086

Other

5,642

5,071

Allowance for doubtful accounts

(721)

(693)

%
54.2%

II Noncurrent assets

186,62247.1%

195,076

45.8%

1. Property, plant and equipment

114,45828.9%

114,030

26.8%

Buildings and structures

46,52045,533

Machinery, equipment and vehicles

30,402

29,345Land

20,214

20,285706

665

10,20011,941

Lease assetsConstruction in progress
Other

6,413

6,259

2. Intangible assets

29,095

7.3%

Goodwill

21,98522,989

Other

7,109

7,140

3. Investments and other assets

43,069Investment securities

28,152

38,868Deferred tax assets

9,727

6,614

Other

5,189

5,433

Total assets

395,8942

10.9%

30,129100.0%

50,915425,507

7.1%

11.9%

100.0%

(Millions of yen)
As of June 30, 2010
Amount(Liabilities)
I Current liabilities%

78,205

19.7%

As of March 31, 2010
Amount%99,731

Notes and accounts payable-trade27,96727,367

Short-term loans payable

10,00020,000

228

219

3,848

12,994

Lease obligations
Income taxes payable
Deferred tax liabilities-Provision for bonuses

7

2,537

4,898

40

161

Notes and accounts payable - facilities

9,351

8,031

Other

24,231

26,049Provision for directors' bonuses

II Noncurrent liabilities

5,881

Lease obligations

465

463

940

1,367
586

4,677
658

Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits

1.5%

8,636

767

Asset retirement obligations
Other

2.0%

-

2,684

Total liabilities(Net assets)
I Shareholders' equity

23.5%

2,795

84,08621.2%

108,367

25.5%

343,38586.7%

337,633

79.3%

Capital stock

38,716

38,716

Capital surplus

59,03059,030Retained earnings

322,457

316,703

Treasury stock(76,819)(76,817)

II Valuation and translation adjustments(31,791)(8.0%)(20,711)(4.9%)

Valuation difference on available-for-sale securities(2,363)Foreign currency translation adjustment(29,428)
214

0.1%(23,046)218

0.1%

311,80778.8%

317,13974.5%

395,894

100.0%

425,507100.0%III Minority interests
Total net assets
Total liabilities and net assets

32,335

(2) Consolidated Statements of Income(Millions of yen)Three months ended
June 30, 2009
Amount%Three months ended
June 30, 2010
Amount%I Net sales
II Cost of sales
Gross profit

77,467100.0%

81,234100.0%

35,92846.4%

38,89847.9%

41,53953.6%

42,336

52.1%

III Selling, general and

25,062

32.3%

26,38932.5%

Operating income
IV Non-operating income

16,47621.3%

15,946

19.6%

367

0.5%

administrative expenses

Interest income14267

Dividends income

42

150

Royalty income

40

Foreign exchange gains

325

38－Equity in earnings of affiliates

39

34

Other

120

711

0.9%

76

V Non-operating expenses
Interest expenses

45

28

Sales discounts
Foreign exchange losses

146－

3,439

Loss on disposal of inventories

41

35

Other

20

Ordinary income
VI Extraordinary income
Gain on sales of noncurrent assets
Reversal of allowance for doubtful accounts

144

253

0.3%

16,93421.9%

03,7594.6%

12,554

15.5%

497

0.6%

190.1%

13,031

16.0%

200

Gain on contribution of securities to retirement
benefit trust

111－

10.0%

494

2－

20.0%

1516,933

21.9%

VII Extraordinary losses
Loss on disposal of noncurrent assets
Directors' retirement benefit

Income before income taxes
Income taxes-current

4,081

Income taxes-deferred

2,027

Income before minority interst
Minority interests in income

Net income for the period

4

3

2,666
6,108

7.9%

－
11
10,812

－
0.0%
14.0%

1,552

4,219

5.2%

8,812
19
8,792

10.8%
0.0%
10.8%

(3) Consolidated Statements of Cash FlowsI(Millions of yen)Three months endedThree months ended

June 30, 2009

June 30, 2010

AmountAmountNet cash provided by (used in) operating activities
Income before income taxes
Depreciation and amortization
Amortization of goodwill
Equity in (earnings) losses of affiliates
Increase (decrease) in provision for retirement benefits
Increase(decrease) in reserve for retirement benefits for directors
and corporate auditors
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in provision for directors' bonuses
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Loss (gain) on disposal of noncurrent assets
Loss (gain) on sales of noncurrent assets
Loss (gain) on securities contribution to employees retirement
benefits trust
Transfer of securities to retirement benefit trust
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Other, net

Sub-totalInterest and dividends income received
Interest expenses paid
Income taxes paid

Net cash provided by (used in) operating activities

16,933
4,010
471
(39)
392

13,031
4,132
408
(34)
(3,137)

－(72)

(31)
(125)

50(121)

(184)
45
13
2(0)

(217)
28
2,521
3(2)

－(494)－(1,828)(1,269)(1,563)64
16,889346(48)(5,674)
11,5123,200(810)112
788(3,574)
15,811376(32)(11,936)
4,220

II Net cash provided by (used in) investment activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment
Proceeds from sales of property, plant and equipment
Purchase of intangible assets
Purchase of investment securities

Net cash provided by (used in) investment activities(8,745)

(859)

2,239
(4,142)0(264)(106)(11,018)

1,673(3,529)2(405)(10)(3,128)(2,100)(2)(47)(3,038)(5,188)955(10,000)(2)(56)(3,038)(13,097)(3,349)(3,739)55,06751,328(15,354)
84,877
69,522

III Net cash provided by (used in) financing activities
Net increase (decrease) in short-term loans payable
Purchase of treasury stock
Repayments of finance lease obligations
Cash dividends paid

Net cash provided by (used in) financing activities
IV Effect of exchange rate change on cash and cash equivalents
V Net increase (decrease) in cash and cash equivalents
VI Cash and cash equivalents at beginning of period
VII Cash and cash equivalents at end of period

55. Segment Information(1) The First Quarter of Fiscal Year Ended March 31, 2010
[Business segments](Millions of yen)Three months ended
June 30, 2009
AmountOperatingincomeSales
General hospital products
Cardiac & Vascular products
Blood transfusion products
Consumer Healthcare products
Corporate expenses
Total

36,64333,2795,651
1,892－77,467

8,6079,830843333(3,138)16,476(Note) Main products belonging to each product segment

Product segments

Main products

General Hospital products
Disposable medical devices
and Medical electronics

Syringes, Needles, Solution sets, I.V.catheters, Blood collection tubes, Infusion pumps,
Syringe pumps, etc.

Pharmaceuticals

I.V.solutions, Prefilled syringes, Nutritious food, etc.

CAPD products

CAPD systems

Diabetes care products

Blood glucose monitoring systems

Home parenteral nutrition and oxygen

Home parenteral nutrition system, Home oxygen therapy system, etc.

Cardiac and Vascular productsInterventional systemsAngiographic catheters, PTCA balloon catheters, Coronary stents, Neuro interventionalcoils, etc.

Cardiovascular systems

Oxygenerators, Cardio-pulmonary bypass system, etc.

Vascular grafts

Artificial vascular grafts, Stent grafts

Blood Transfusion products

Blood bags, Automated blood processing, etc.

Consumer Healthcare products

Digital Thermometers, Blood pressure monitors, Blood glucose monitors (OTC), etc.

[Geographic segments](Millions of yen)Three months ended
June 30, 2009
AmountSales to customer

JapanEuropeAmericas
Asia and others
Corporate expenses / eliminations
Total

42,822
13,406
13,7117,527－
77,467

Internal sales

11,746
1,150
1,520
3,698
(18,116)－[Sales results by regions](Millions of yen)Three months ended
June 30, 2009
Amount%Japan
42,82055.3%
Europe13,406
17.3%
Americas13,711
17.7%
Asia and others
7,529
9.7%
Total
77,467100.0%(Note) Sales in 'Asia and others' includes direct sales from Japan.

6

Operatingincome

14,374
2,452
883
2,099
(3,334)
16,476

(2) The First Quarter of Fiscal Year Ending March 31, 2011
Starting in the first quarter of the current fiscal year, the "Accounting Standard for Disclosuresabout Segments of an Enterprise and Related Information" (Accounting Standard Board of Japan(ASBJ) Statement No.17, March 27, 2009) and "Guidance on Accounting Standard for Disclosuresabout Segments of an Enterprise and Related Information" (ASBJ Guidance No.20, March 21,2008) have been applied. Therefore, the lists of the segment information for Fiscal Year 2010 are
newly reformed as follows:[Business segments](Millions of yen)Three months ended
June 30, 2010
AmountSales to customer

Internal sales

Segment
profitGeneral Hospital business
37,077－6,337
Cardiac & Vascular business
36,447－9,598
Blood Transfusion business
6,443－
813
Consumer Healthcare business802－(373)
Subtotal
80,771－
16,375Adjustment
463－
(429)
Total
81,234－
15,946
Notes:
1. The (429) million yen adjustment to segment profit is the sum of the (506) million yen
for Inventories and the 77 million yen for others.
2. Segment profit is adjusted to be consistent with operating income shown on thequarterly consolidated income statement.
(Note) Main products belonging to each business segment

Business segments

Main products

General Hospital business
Disposable medical devices
and Medical electronics

Solution sets, I.V.catheters, Infusion pumps, Syringe pumps, Syringes, Needles, Bloodcollection tubes, Home parenteral nutrition system, Home oxygen therapy system, etc.

Pharmaceuticals

I.V.solutions, Nutritious food, Prefilled syringes, CAPD systems, etc.

Diabetes care products

Blood glucose monitoring systems

Cardiac and Vascular business
Interventional systems

Angiographic catheters, PTCA balloon catheters, Coronary stents, Neuro interventionalcoils, etc.

Cardiovascular systems

Oxygenerators, Cardio-pulmonary bypass system, LVA system, etc.

Vascular grafts

Artificial vascular grafts, Stent grafts

Blood Transfusion business

Blood bags, Automated blood processing, etc.

Consumer Healthcare business

Digital Thermometers, Blood pressure monitors, Blood glucose monitors (OTC), etc.

(Supplemetary Information)[Geographic segments](Millions of yen)Three months ended
June 30, 2010
AmountSales to customer

JapanEurope
Americas
Asia and others
Subtotal
Corporate expenses / eliminations
Total

42,54813,78815,782
9,114
81,234－
81,234
7

Internal sales

13,996
988
1,464
3,839
20,288(20,288)－Operatingincome

13,132
1,982
1,852
2,246
19,213(3,267)
15,946